Patients demonstrated change from baseline in both QMG score (P = .0003) and MG-ADL score (P = .0006).
The drug was also well tolerated in this population of patients.
Approximately 5–8 % of MG patients test positive for antibodies against muscle-specific tyrosine kinase (MuSK). MuSK is a receptor tyrosine kinase required for the formation and maintenance of the neuromuscular junction.
In MG, antibodies block, alter, or destroy the acetylcholine receptors at the neuromuscular junction. The condition is usually treated with acetylcholinesterase inhibitors that can increase the concentration of acetylcholine at the neuromuscular junction.